Fucoxanthinol

Overview

Fucoxanthin ol, a carotenoid, is a deacetylated Fucoxanthin ( HY-N2302 ) metabolite with oral activity, and inhibits rat pancreatic lipase with an IC 50 of 764 nM. Fucoxanthin ol reduces expression of Bcl-2 , Bcl-xL , survivin , XIAP , cIAP2 , cyclin D1 , cyclin D2 , cyclin E , CDK4 , CDK6 , β-catenin , JunD , PPARγ , and induces GADD45α expression. Fucoxanthin ol activates caspase-3 , caspase-8 , caspase-9, Nrf2 / Keap1 / ARE pathway, and inhibits activation of Akt , NF-κB , AP-1 , PDPK1 , GSK3β phosphorylation. Fucoxanthin ol induces apoptosis , G0/G1 cell cycle arrest, inhibits cancer cell viability, proliferation, migration, invasiveness, tumour growth, adipocyte differentiation, oxidative stress, neurotoxicity, triglyceride absorption, angiogenesis, and obesity-induced inflammation. Fucoxanthin ol can be used for the research of osteosarcoma, leukemia, lymphoma, adult T-cell leukemia, prostate cancer , colon cancer , breast cancer , hypertriglyceridaemia, Alzheimer’s disease, Parkinson’s disease, obesity, insulin resistance, malignant melanoma, and type II diabetes.

Application

Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Glucose Metabolism | Products > Disease Areas > Lipid Metabolism | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Melanoma | Products > Disease Areas > Osteosarcoma | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Type 2 Diabetes | Products > Disease Areas > Obesity | Products > Disease Areas > Hypertriglyceridemia | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > NF-κB | Products > Research Areas > Neurological Disease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > IAP | Products > Signaling Pathways > Lipase | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Bcl-2 Family | Products > Signaling Pathways > CDK

Product Information

• Catalog No.: HY-N11231
• CAS No.: 7176-02-5
• Molecular Formula: C40H56O5
• Molecular Weight: 616.87
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source